

ACTIVE PHARMACEUTICAL INGREDIENTS PORTFOLIO		
API	CAS	THERAPEUTIC CATHEGORY
Abiraterone acetate	154229-18-2	Antiandrogen
Aprepitant	170729-80-3	Antiemetic
Atovaquone	95233-18-4	Antimalarial
Atracurium besylate	64228-81-5	NMBA
Atropine base	51-55-8	Anticholinergic
Atropine sulfatate	55-48-1	Anticholinergic
Benazepril HCl	86541-74-4	ACE Inhibitor
Bortezomib	179324-69-7	Antineoplastic
Captopril	62571-86-2	ACE Inhibitor
Cisatracurium besilate	96946-42-8	NMBA
Decitabine	2353-33-5	Antineoplastic
Desloratadine	100643-71-8	Antihistaminic
Deutetrabenazine	1392826-25-3	VMAT2 inhibitor
Dolasetron mesylate	115956-13-3	Antiemetic
Enalapril maleate	76095-16-4	ACE inhibitor
Enalaprilat	76420-72-9	ACE inhibitor
Enzalutamide	915087-33-1	Antiandrogen
Everolimus	159351-69-6	Antineoplastic
Fexofenadine HCl	153439-40-8	Antihistaminic
Flupirtine maleate	75507-68-5	Analgesic
Fosaprepitant dimeglumine	265121-04-8	Antiemetic
Gefitinib	184475-35-2	Antineoplastic
Gemcitabine HCl	122111-03-9	Antineoplastic
Lisinopril	83915-83-7	ACE inhibitor

*Samples for R&D use in the United States are available as permitted under 35 USC § 271 (e)(1).
 Product currently under patent protection could be available only for R&D purposes, if this is allowed by local laws.
 Products covered by valid patents in any country are not offered or supplied to these countries. However, the final responsibility lies exclusively on the buyer.*

API	CAS	THERAPEUTIC CATHEGORY
Loratadine	79794-75-5	Antihistaminic
Metformin HCl	1115-70-4	Type 2 diabetes
Methotrexate	59-05-2	Antineoplastic
Milrinone	78415-72-2	PDE3 inhibitor
Mivacurium chloride	106861-44-3	NMBA
Moexipril HCl	82586-52-5	ACE inhibitor
Palonosetron HCl	135729-62-3	Antiemetic
Pemetrexed disodium	150399-23-8	Antineoplastic
Perindopril arginine	612548-45-5	ACE inhibitor
Perindopril erbumine	107133-36-8	ACE inhibitor
Pirfenidone	154229-18-2	Antifibrotic
Quinapril HCl	82586-55-8	ACE inhibitor
Ramipril	87333-19-5	ACE inhibitor
Rocuronium bromide	119302-91-9	NMBA
Sirolimus	53123-88-9	Immunosuppressant
Solifenacin succinate	242478-38-2	Urinary Incontinence
Sugammadex sodium	343306-79-6	NMB Reversal
Tacrolimus	104987-11-3	Immunosuppressant
Tetrabenazine*	58-46-8	VMAT2 inhibitor
Tipiracil HCl	183204-72-0	Antimetabolite
Trandolapril	87679-37-6	ACE inhibitor
Trifluridine	70-00-8	Antiviral/Antineoplastic
Vecuronium HBr	50700-72-6	NMBA

**Only for non-US territories*

Farmhispania Group also offers exclusive contract development under strict confidentiality

Samples for R&D use in the United States are available as permitted under 35 USC § 271 (e)(1).
 Product currently under patent protection could be available only for R&D purposes, if this is allowed by local laws.
 Products covered by valid patents in any country are not offered or supplied to these countries. However, the final responsibility lies exclusively on the buyer.